The start to the year was largely unaffected by the Middle East conflict, but the lagging effect of high bunker fuel prices will be felt from the second quarter onward.
Continue reading →
As if the Strait of Hormuz and Red Sea haven’t caused enough concern for commercial shipping, Lars Jensen warns of the potential for weather-related disruptions once again at the canal by year-end.
Continue reading →
The railroads say they plan to file an updated merger application on April 30, addressing many of the complaints that caused regulators to deem their original application “incomplete.”
Continue reading →
The headline fight in FY2025 pharma happened at the very top of the leaderboard, where Keytruda held the No. 1 brand slot even as Lilly’s tirzepatide and Novo’s semaglutide passed it at the molecule level. We covered that reshuffle in a separate analysis. Look past Keytruda, Mounjaro...
Merck’s Keytruda (pembrolizumab) remained pharma’s No. 1 brand in FY2025 with $31.7 billion in sales. But it is no longer the industry’s top-selling medicine at the molecule level. Lilly’s tirzepatide franchise, spanning Mounjaro ($22.965 billion) and Zepbound ($13.542...
Cybersecurity researchers have flagged yet another evolution of the ongoing GlassWorm campaign, which employs a new Zig dropper that’s designed to stealthily infect all integrated development environments (IDEs) on a developer’s machine. The technique has been discovered in...
While much of the discussion on AI security centers around protecting ‘shadow’ AI and GenAI consumption, there’s a wide-open window nobody’s guarding: AI browser extensions. A new report from LayerX exposes just how deep this blind spot goes, and why AI...
Hungarian domestic intelligence, the national police in El Salvador, and several U.S. law enforcement and police departments have been attributed to the use of an advertising-based global geolocation surveillance system called Webloc. The tool was developed by Israeli company Cobwebs...
Many promising life science innovations struggle to achieve widespread adoption – but why? What differentiates technologies that succeed in real laboratory environments from those that don’t, and what can be done to ensure more tools fulfill their potential? In this interview, Dale Gordon...